 |
|
Topiramate for Migraine Prevention
A Randomized Controlled Trial
Jan Lewis Brandes, MD;
Joel R. Saper, MD;
Merle Diamond, MD;
James R. Couch, MD, PhD;
Donald W. Lewis, MD;
Jennifer Schmitt, MS;
Walter Neto, MD;
Stefan Schwabe, MD;
David Jacobs, MD; for the MIGR-002 Study Group
JAMA. 2004;291:965-973.
Context Small open-label and controlled trials suggest that the antiepileptic drug topiramate is effective for migraine prevention.
Objective To assess the efficacy and safety of topiramate for migraine prevention in a large controlled trial.
Design, Setting, and Patients A 26-week, randomized, double-blind, placebo-controlled study was conducted during outpatient treatment at 52 North American clinical centers. Patients were aged 12 to 65 years and had a 6-month history of migraine (International Headache Society criteria) and 3 to 12 migraines a month but no more than 15 headache days a month during a 28-day prospective baseline phase.
Interventions After a washout period, patients meeting entry criteria were randomized to topiramate (50, 100, or 200 mg/d) or placebo. Topiramate was titrated by 25 mg/wk for 8 weeks to the assigned or maximum tolerated dose, whichever was less. Patients continued receiving that dose for 18 weeks.
Main Outcome Measures The primary efficacy measure was change from baseline in mean monthly migraine frequency. Secondary efficacy measures included responder rate (proportion of patients with  50% reduction in monthly migraine frequency), reductions in mean number of monthly migraine days, severity, duration, and days a month requiring rescue medication, and adverse events. The month of onset of preventive treatment action was assessed.
Results Of 483 patients randomized, 468 provided at least 1 postbaseline efficacy assessment and comprised the intent-to-treat population. Mean monthly migraine frequency decreased significantly for patients receiving topiramate at 100 mg/d (-2.1, P = .008) and topiramate at 200 mg/d (-2.4, P<.001) vs placebo (-1.1). Statistically significant reductions (P<.05) occurred within the first month with topiramate at 100 and 200 mg/d. The responder rate was significantly greater with topiramate at 50 mg/d (39%, P = .01), 100 mg/d (49%, P<.001), and 200 mg/d (47%, P<.001) vs placebo (23%). Reductions in migraine days were significant for the 100-mg/d (P = .003) and 200-mg/d (P<.001) topiramate groups. Rescue medication use was reduced in the 100-mg/d (P = .01) and 200-mg/d (P = .005) topiramate groups. Adverse events resulting in discontinuation in the topiramate groups included paresthesia, fatigue, and nausea.
Conclusion Topiramate showed significant efficacy in migraine prevention within the first month of treatment, an effect maintained for the duration of the double-blind phase.
Author Affiliations: Nashville Neuroscience Group, Nashville, Tenn (Dr Brandes); Michigan Head Pain and Neurological Institute, Ann Arbor (Dr Saper); Diamond Headache Clinic, Chicago, Ill (Dr Diamond); University of Oklahoma Health Sciences Center, Oklahoma City (Dr Couch); Children's Hospital of the King's Daughters, Norfolk, Va (Dr Lewis); and Johnson & Johnson Pharmaceutical Research and Development, Raritan, NJ (Drs Neto, Schwabe, and Jacobs and Ms Schmitt).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Paroxysmal hemicrania responding to topiramate
Cohen and Goadsby
BMJ Case Reports 2009;2009:bcr0620092007-bcr0620092007.
ABSTRACT
| FULL TEXT
Assessing and Managing All Aspects of Migraine: Migraine Attacks, Migraine-Related Functional Impairment, Common Comorbidities, and Quality of Life
Buse et al.
Mayo Clin Proc. 2009;84:422-435.
ABSTRACT
| FULL TEXT
Modern Management of the Migraine Headache
Pesaturo and Wooding
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2009;3:147-159.
ABSTRACT
Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for Migraine Prevention in Pediatric Subjects 12 to 17 Years of Age
Lewis et al.
Pediatrics 2009;123:924-934.
ABSTRACT
| FULL TEXT
Oxcarbazepine in migraine headache: A double-blind, randomized, placebo-controlled study
Silberstein et al.
Neurology 2008;70:548-555.
ABSTRACT
| FULL TEXT
Resource use associated with topiramate in migraine prophylaxis
Feliu et al.
Am J Health Syst Pharm 2007;64:1483-1491.
ABSTRACT
| FULL TEXT
Analysis of Pooled Data From Two Pivotal Controlled Trials on the Efficacy of Topiramate in the Prevention of Migraine
Freitag et al.
JAOA: Journal of the American Osteopathic Association 2007;107:251-258.
ABSTRACT
| FULL TEXT
Topiramate in the Prophylaxis of Pediatric Migraine: A Double-Blind Placebo-Controlled Trial
Lakshmi et al.
J Child Neurol 2007;22:829-835.
ABSTRACT
Pediatric Migraine: Pharmacologic Agents for Prophylaxis
Eiland et al.
The Annals of Pharmacotherapy 2007;41:1181-1190.
ABSTRACT
| FULL TEXT
A Practical Approach to Headache Treatment
Tucker
Journal of Pharmacy Practice 2007;20:123-136.
ABSTRACT
Medicines for migraine
Ryan
EDUCATION AND PRACTICE 2007;92:ep50-ep55.
FULL TEXT
Paroxysmal hemicrania responding to topiramate
Cohen and Goadsby
J. Neurol. Neurosurg. Psychiatry 2007;78:96-97.
ABSTRACT
| FULL TEXT
Assessing the Ability of Topiramate to Improve the Daily Activities of Patients With Migraine
Brandes et al.
Mayo Clin Proc. 2006;81:1311-1319.
ABSTRACT
| FULL TEXT
Update in neurology.
Holloway and Jozefowicz
ANN INTERN MED 2006;144:421-426.
FULL TEXT
Topiramate in essential tremor: A double-blind, placebo-controlled trial
Ondo et al.
Neurology 2006;66:672-677.
ABSTRACT
| FULL TEXT
Chronic Daily Headache
Dodick
NEJM 2006;354:158-165.
FULL TEXT
Recent advances in the diagnosis and management of migraine
Goadsby
BMJ 2006;332:25-29.
FULL TEXT
Advances in the understanding of headache
Goadsby
Br Med Bull 2005;73-74:83-92.
ABSTRACT
| FULL TEXT
Botulinum Toxin Type A for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double-Blind, Placebo-Controlled Trial
Silberstein et al.
Mayo Clin Proc. 2005;80:1126-1137.
ABSTRACT
Acupuncture for Patients With Migraine: A Randomized Controlled Trial
Linde et al.
JAMA 2005;293:2118-2125.
ABSTRACT
| FULL TEXT
Pediatric Migraine: Recognition and Treatment
Hershey and Winner
JAOA: Journal of the American Osteopathic Association 2005;105:2S-8S.
ABSTRACT
| FULL TEXT
Advances in Migraine Treatment
Nissan and Diamond
JAOA: Journal of the American Osteopathic Association 2005;105:9S-15S.
ABSTRACT
| FULL TEXT
Review: anticonvulsants are better than placebo for reducing the frequency of migraine attacks
Chessman
Evid. Based Med. 2005;10:16-16.
FULL TEXT
From the Library
Br J Ophthalmol 2004;88:726-726.
FULL TEXT
Topiramate Is Effective for Preventing Migraines
JWatch General 2004;2004:2-2.
FULL TEXT
|
